Dinu Sen, CEO and president of CURx Pharmaceuticals, said his company is working to develop a broad-spectrum, inhaled antibiotic.

Dinu Sen, CEO and president of CURx Pharmaceuticals, said his company is working to develop a broad-spectrum, inhaled antibiotic. Photo by Stephen Whalen.

The rising number of drug-resistant “superbugs” ­– and the lack of new therapies to fight them ­– has prompted concerned public health officials to offer incentives to drugmakers to lure them back into the abandoned field of antibiotics...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129